Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENMD-2076 in Advanced Fibrolamellar Carcinoma
NCT02234986Phase 2Completed
- Sponsor
- CASI Pharmaceuticals, Inc.
- Start
- Oct 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enmd-2076 in fibrolamellar carcinoma (FLC), sponsored by CASI Pharmaceuticals, Inc.. Started Oct 2015; status: completed.
02
Drugs
enmd-2076
03
Conditions
fibrolamellar carcinoma (FLC)
Beyond the preview
Go deeper on NCT02234986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02234986.